China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

China's E-Commerce Is Not as Bad as the Stock Prices Suggest

How to Stimulate China's Consumption, Part IV：Consumption Voucher Is Effective

The 3rd Plenum of CCPCC Announced An Courageous But Tough-To-Execute Communique

How to Stimulate China's Consumption? Part I

How to Stimulate China's Consumption, Part II

Andy Fu

Thematic (Sector/Industry)

China Pharmaceuticals, biotechnology and life sciences / Thematic (Sector/Industry)

<ul>
<li>As Chinese population ages, healthcare is a major source of consumption. Yet we are the most pessimistic for it to become a pillar of consumption;</li>
<li>Low healthcare spending in China is achieved by underpaying doctors and nurses. Enhancing life quality, instead of only curing disease, can meaningfully improve consumption; </li>
<li>However, consumer healthcare begets a larger and more common economic phenomenon, which is underpricing. The issue of underpricing stems from low compliance cost, in our opinion.</li>
</ul>


As Chinese population ages, healthcare is a major source of consumption. Yet we are the most pessimistic for it to become a pillar of consumption;
Low healthcare spending in China is achieved by underpaying doctors and nurses. Enhancing life quality, instead of only curing disease, can meaningfully improve consumption; 
However, consumer healthcare begets a larger and more common economic phenomenon, which is underpricing. The issue of underpricing stems from low compliance cost, in our opinion.


Shanghai Fosun Pharmaceutical (Group) (2196 HK)

Ping An Healthcare and Technology (1833 HK)

How to Stimulate China's Consumption, Part III

China Health Care

How to Stimulate China's Consumption, Part III